High-content Screening Market Research Report and Forecast up to 2027 High-content Screening Market - Global Industry An

High-content
Screening
Market
-
Global
Industry Analysis, Size, Share, Growth, Trends,
and Forecast 2017 - 2025
High-content screening (HCS) or high-content analysis (HCA) (also known as
cellomics), is a set of analytical techniques that is applied in genetic research and
drug discovery processes in order to recognize elements such as peptides, small
molecules, or genetic materials (such as RNAi) that have the potential to modify the
phenotype of a cell in a certain manner. High-content screening employs a set of
analytical procedures such as multi-parameter image processing, automated
microscopy, fluorescence imaging, and other visualization processes to get
quantitative data from cell populations. The phenotypic alterations may comprise
rise or decrease in the production of cellular produces such as proteins, or changes
in the morphology of a cell. High-content screening can be employed to analyze
whole cells or certain components of cells with simultaneous data collection of
numerous factors.
View Report @ http://www.transparencymarketresearch.com/high-content-
screening-market.html
The high-content screening market is anticipated to witness significant growth
during the forecast period, owing to the ability of HCS to study several parameters
in a complex biological system simultaneously. High-content screening (HCS) is also
expected to generate high demand due to its numerous applications in pre-clinical,
clinical trial, and later stages of drug development. High-content screening can also
be used to calculate cellular toxicity, to recognize and validate new drug targets or
new prime combinations, and to propose pathways or molecular targets of orphan
compounds. The steep rise in demand for better and cost-effective methods of drug
discovery and clinical trials and increased knowledge of pharmacogenetics and
pharmacokinetics are factors inclining the clinicians toward high-content screening
of certain medications. Rapid increase in the prevalence of complex neurological
diseases and genetic disorders has fueled the demand for high-end R&D activities.
This, in turn, is anticipated to boost the high-content screening market during the
forecast period. Moreover, increasing investment in research and development in
cellular science of novel molecules by private and government bodies is expected to
propel the HCS market in the near future. In addition, development of innovative
tools for health care management is propelling the market further. However, low
research and development (R&D) yields, high cost of infrastructure, stringent
regulatory framework, and lack of trained resources are some of the restraints for
the high-content screening market.